These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22541618)

  • 41. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
    Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
    Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mepolizumab treatment for asthma.
    Robinson DS
    Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease.
    Devos R; Plaetinck G; Cornelis S; Guisez Y; Van der Heyden J; Tavernier J
    J Leukoc Biol; 1995 Jun; 57(6):813-9. PubMed ID: 7790761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IL-5 and eosinophilia.
    Takatsu K; Nakajima H
    Curr Opin Immunol; 2008 Jun; 20(3):288-94. PubMed ID: 18511250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on reslizumab for eosinophilic asthma.
    Cardet JC; Israel E
    Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Severe refractory eosinophilic asthma].
    Jäger-Becker D
    MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
    [No Abstract]   [Full Text] [Related]  

  • 48. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge.
    Imaoka H; Campbell H; Babirad I; Watson RM; Mistry M; Sehmi R; Gauvreau GM
    Clin Exp Allergy; 2011 Dec; 41(12):1740-6. PubMed ID: 21762225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review.
    Patterson MF; Borish L; Kennedy JL
    J Asthma Allergy; 2015; 8():125-34. PubMed ID: 26604804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome.
    Rosenwasser LJ; Rothenberg ME
    J Allergy Clin Immunol; 2010 Jun; 125(6):1245-6. PubMed ID: 20513522
    [No Abstract]   [Full Text] [Related]  

  • 52. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.
    Pelaia C; Calabrese C; Vatrella A; Busceti MT; Garofalo E; Lombardo N; Terracciano R; Pelaia G
    Biomed Res Int; 2018; 2018():4839230. PubMed ID: 29862274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 55. Reslizumab: First Global Approval.
    Markham A
    Drugs; 2016 May; 76(8):907-11. PubMed ID: 27125787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders.
    Heinisch IV; Bizer C; Volgger W; Simon HU
    J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.
    Schrezenmeier H; Thomé SD; Tewald F; Fleischer B; Raghavachar A
    Exp Hematol; 1993 Feb; 21(2):358-65. PubMed ID: 8425573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
    Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
    Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eosinophilic disorders in children.
    Wagelie-Steffen A; Aceves SS
    Curr Allergy Asthma Rep; 2006 Nov; 6(6):475-82. PubMed ID: 17026874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-IL5 therapy for asthma and beyond.
    Mukherjee M; Sehmi R; Nair P
    World Allergy Organ J; 2014; 7(1):32. PubMed ID: 25709744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.